Evolus to Report Third Quarter 2021 Results and Provide Business Update

Rhea-AI Summary

Evolus, Inc. (NASDAQ: EOLS) has announced it will report its Q3 2021 financial results and provide a business update on November 2, 2021, before U.S. market opening. Management will hold a conference call at 9:00 a.m. ET to discuss these results, followed by a Q&A session. Interested parties can participate by calling (877) 407-6184 for U.S. callers or (201) 389-0877 for international callers, or via a live webcast on Evolus' Investor Relations page. A replay of the call will be available post-event.

News Market Reaction – EOLS

+1.24%

+1.24% Session move

In the trading session that priced this news, EOLS gained 1.24%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWPORT BEACH, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its third quarter 2021 financial results and provide a business update on Tuesday, November 2, 2021, prior to the open of the U.S. financial markets.

Management will host a conference call and live webcast to discuss Evolus’ financial results at 9:00 a.m. ET that same day. A question-and-answer session will follow management’s remarks.

To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect to the live webcast via the link on the Investor Relations page of the Evolus website at www.evolus.com.

Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international). An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.

About Evolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com.

Jeuveau^® is a registered trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Evolus, Inc. Contacts:

Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com

FAQ

When will Evolus report its Q3 2021 financial results?

Evolus will report its Q3 2021 financial results on November 2, 2021.

What time is the Evolus conference call for Q3 2021 results?

The Evolus conference call will take place at 9:00 a.m. ET on November 2, 2021.

How can I participate in Evolus' conference call?

You can participate in the Evolus conference call by calling (877) 407-6184 for U.S. callers or (201) 389-0877 for international callers, or join via the live webcast on their website.

Is there a replay available for the Evolus conference call?

Yes, a replay of the Evolus conference call can be accessed by calling (877) 660-6853 for U.S. callers or (201) 612-7415 for international callers after the event.

What is Jeuveau and how is it related to Evolus?

Jeuveau is a neurotoxin product developed by Evolus, approved by the FDA in 2019, dedicated exclusively to aesthetics.